West Pharmaceutical Services, Inc. — Fiscal 2023 Form 10-K Summary
Business context and reporting period
West is a global manufacturer of containment, packaging, drug-delivery and contract-manufacturing solutions for injectable pharmaceuticals, biologics, diagnostics and medical devices. Operations are organized into Proprietary Products and Contract-Manufactured Products. The filing covers the fiscal year ended December 31, 2023, and was filed February 20, 2024. Sales outside the United States represented 58.0% of 2023 net sales.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net sales | $2,949.8 million | $2,886.9 million | +2.2% |
| Gross profit | $1,129.2 million | $1,136.2 million | -0.6% |
| Gross margin | 38.3% | 39.4% | -1.1 pts |
| Operating profit | $676.0 million | $734.0 million | -7.9% |
| Operating margin | 22.9% | 25.4% | -2.5 pts |
| Net income | $593.4 million | $585.9 million | +1.3% |
| Diluted EPS | $7.88 | $7.73 | +1.9% |
| Operating cash flow | $776.5 million | $724.0 million | +7.3% |
| Capital expenditures | $362.0 million | $284.6 million | +27.2% |
- Proprietary Products sales declined 0.4% to $2,397.3 million, primarily because COVID-related sales fell approximately $320 million. Growth in high-value components, delivery devices and pricing substantially offset that decline.
- Contract-Manufactured Products sales increased 15.0% to $552.5 million, driven by injection-related and healthcare diagnostic devices and pricing.
- Adjusted operating profit was $690.6 million, with an adjusted margin of 23.4%, compared with $762.0 million and 26.4% in 2022. Adjusted diluted EPS was $8.08 versus $8.58.
- Cash and cash equivalents were $853.9 million at year-end, compared with $894.3 million in 2022. Working capital was $1,264.6 million, versus $1,400.5 million.
- Total debt was $206.8 million, including $134.0 million classified as current. The Company had no borrowings under its $500 million revolving credit facility and approximately $497.6 million of available capacity, including letters of credit.
- West repurchased 1.27 million shares for $438.3 million during 2023 and paid $57.0 million in dividends. The remaining authorization under the $1 billion repurchase program was approximately $561.7 million at December 31, 2023.
Material changes versus the prior comparable period
- Revenue growth was modest and was more than offset by a sharp reduction in high-margin COVID-related revenue within Proprietary Products.
- Consolidated gross margin declined because of lower COVID-related sales, approximately $21 million less in fees from COVID-19 supply agreements, and inflationary compensation costs.
- SG&A increased 11.5% to $353.4 million, primarily due to compensation, incentive compensation and professional-service costs. R&D increased 16.9% to $68.4 million, including $3.5 million of incremental research on glass systems.
- Operating profit included an $11.6 million loss on the sale of a manufacturing facility, $4.3 million of cost-investment impairment charges and $9.6 million of asset impairments. These were partly offset by a $2.8 million restructuring benefit and a $3.8 million favorable legal settlement.
- 2022 included a $52.2 million pension settlement charge that did not recur in 2023. Higher 2023 interest income and the absence of that pension charge helped net income increase despite lower operating profit.
- Capital expenditures increased to support manufacturing capacity and improve manufacturing lead times. Property, plant and equipment, net, increased to $1,413.3 million from $1,158.3 million.
Guidance, outlook, commentary and risks
The filing does not provide a clear quantitative 2024 revenue or earnings guidance figure. Management expects cash on hand, operating cash flow and revolving-credit availability to meet foreseeable liquidity needs, and expects continued compliance with debt covenants during 2024. The 2022 restructuring plan is expected to generate annualized savings of approximately $22 million to $24 million; approximately $3.0 million of related obligations remained at year-end 2023.
- Management expects near-term operating performance to remain subject to volatility from inflation, raw-material costs, foreign exchange and supply-chain conditions. Higher raw-material costs were experienced in 2023.
- Key business risks include continued normalization of COVID-related demand, customer pricing pressure, pharmaceutical and healthcare consolidation, dependence on injectable drug products, product-development and regulatory delays, manufacturing concentration and reliance on single-source suppliers.
- International operations expose West to currency, geopolitical, regulatory, tax and anti-corruption risks. Argentina generated foreign-exchange transaction losses in 2023.
- One customer represented 10.9% of consolidated sales, or $322.1 million, creating customer-concentration risk. The ten largest customers represented 41.4% of sales.
- Debt maturities include $134.0 million in 2024 and $73.0 million in 2027. The Company was in compliance with all debt covenants at year-end.
- Unconditional contractual commitments totaled $298.3 million, including $76.8 million due in 2024. The filing reports no material legal proceedings and no cybersecurity incidents that materially affected operations or financial condition.
- PwC issued unqualified opinions on the financial statements and internal control over financial reporting. Income taxes were identified as the critical audit matter because of the complexity of the Company’s global tax position.
Important facts for investors to verify
- Whether growth in high-value components, delivery devices and Contract-Manufactured Products can offset the continuing decline in COVID-related sales.
- Whether capacity investments and pricing actions restore gross and operating margins despite inflation and higher fixed costs.
- The refinancing or repayment plan for the $134.0 million of debt due in 2024 and the continued availability of the revolving credit facility.
- The pace and return on the expanded capital-expenditure program, particularly the $90.2 million invested in Contract-Manufactured Products.
- The durability of customer demand, including concentration involving the customer responsible for 10.9% of sales.
- Potential effects of foreign exchange, raw-material and energy prices, supply interruptions, geopolitical events and regulatory changes on earnings and cash flow.
- The treatment and potential realization of $38.8 million of unrecognized tax benefits and the tax implications of approximately $857 million of foreign undistributed earnings that remain permanently reinvested, excluding certain German earnings.